Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF)
Vactosertib and imatinib combination in patients with advanced desmoid tumor/aggressive fibromatosis (DT/AF) compared with imatinib monotherapy
Dermoid
DRUG: Vactosertib|DRUG: Imatinib
progression-free survival, To evaluate the progression-free survival (PFS) of vactosertib and imatinib combination compared with imatinib alone up to 2 years. The subject will be assessed until disease progression is observed or death, which comes first. The disease progression will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Criteria. The date of progression will be determined by a blinded, independent, central radiologic review (BICR)., 28 days
This is an open-label, multi-center, randomized controlled study to evaluate the safety and efficacy of vactosertib 200 mg BID in combination with imatinib versus imatinib alone.